NCT06970847 2026-03-18
AMPLIFY
Clarity Pharmaceuticals Ltd
Phase 3 Recruiting
Clinical Trials
49 trialsNCT02064673 2026-03-17
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
University of Texas Southwestern Medical Center
Phase 3 Recruiting
NCT07477626 2026-03-17
RADVAN
Sun Yat-sen University
Phase 3 Active not recruiting
NCT06056830 2026-03-16
CLARIFY
Clarity Pharmaceuticals Ltd
Phase 3 Recruiting
NCT04557059 2026-03-13
PRIMORDIUM
Janssen Pharmaceutica N.V., Belgium
Phase 3 Active not recruiting
NCT06925737 2026-03-13
MK-2400-001
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT04720157 2026-03-11
PSMAddition
Novartis
Phase 3 Active not recruiting
NCT04821622 2026-03-11
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
Pfizer
Phase 3 Active not recruiting
NCT06136650 2026-03-09
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT01546987 2026-03-06
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT06691984 2026-03-06
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Amgen
Phase 3 Recruiting
NCT00063882 2026-03-05
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT06551324 2026-03-04
MEVPRO-1
Pfizer
Phase 3 Recruiting
NCT06931340 2026-03-04
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT07028853 2026-03-04
MEVPRO-3
Pfizer
Phase 3 Recruiting
NCT05154162 2026-03-03
PRIMARY2
Peter MacCallum Cancer Centre, Australia
Phase 3 Active not recruiting
NCT04423211 2026-03-02
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT03574571 2026-02-27
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 3 Active not recruiting
NCT04736199 2026-02-27
ARANOTE
Bayer
Phase 3 Completed
NCT06855277 2026-02-24
AcTFirst
Novartis
Phase 3 Recruiting
NCT04689828 2026-02-20
PSMAfore
Novartis
Phase 3 Active not recruiting
NCT04876651 2026-02-20
The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Terminated
NCT06235099 2026-02-18
Solar-Recur
Curium US LLC
Phase 3 Completed
NCT06235151 2026-02-17
Solar-Stage
Curium US LLC
Phase 3 Recruiting
NCT07413120 2026-02-17
Efficacy and Safety of VasoClip® vs. WeckClip® for Robotic Urologic Surgery
Incheon St.Mary's Hospital
Phase 3 Completed
NCT02257736 2026-02-13
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT02531516 2026-02-13
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT06439225 2026-02-11
OPTION-DDR
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT06625034 2026-02-10
Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer
Mayo Clinic
Phase 3 Recruiting
NCT04455750 2026-02-05
CASPAR
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT06563388 2026-02-04
ID-COMET
Roswell Park Cancer Institute
Phase 3 Recruiting
NCT01946204 2026-02-02
SPARTAN
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT02489318 2026-02-02
TITAN
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT05946213 2026-02-02
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NRG Oncology
Phase 3 Recruiting
NCT06764485 2026-01-28
rechARge
Celgene
Phase 3 Recruiting
NCT02003924 2026-01-27
PROSPER
Pfizer
Phase 3 Completed
NCT06470243 2026-01-22
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
SWOG Cancer Research Network
Phase 3 Recruiting
NCT06120491 2026-01-21
EvoPAR-PR01
AstraZeneca
Phase 3 Recruiting
NCT04493853 2026-01-20
CAPItello-281
AstraZeneca
Phase 3 Active not recruiting
NCT06205316 2026-01-20
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Mayo Clinic
Phase 3 Recruiting
NCT03767244 2026-01-16
PROTEUS
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05838716 2026-01-15
ViPER
University of Rochester
Phase 3 Recruiting
NCT04134260 2026-01-14
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
NRG Oncology
Phase 3 Recruiting
NCT04513717 2026-01-14
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
Phase 3 Active not recruiting
NCT06592924 2026-01-14
TRIPLE-SWITCH
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT04647526 2026-01-13
SPLASH
Eli Lilly and Company
Phase 3 Active not recruiting
NCT06235697 2026-01-13
ASCENDE-SBRT
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT01809691 2025-12-31
S1216
SWOG Cancer Research Network
Phase 3 Completed
NCT02051218 2025-12-30
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
Swiss Cancer Institute
Phase 3 Active not recruiting